Purpose of review: To summarize recent findings related to the prevalence, epidemiology, diagnosis, and treatment of male hypogonadism.
Recent findings: Population-based studies indicate that low testosterone levels predict development of type 2 diabetes mellitus, metabolic syndrome, and survival. Although a large clinical trial is needed to assess the long-term benefit-to-risk ratio, testosterone replacement therapy has been shown to have positive effects on sexual function, mood, body composition, muscle mass, and bone density. Due to its potential side effects, careful monitoring for safety is critical, mainly in old men.
Summary: Testosterone replacement therapy is the mainstay of treatment for men with hypogonadism, treatment should be closely monitored in men over age 50.